<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439373</url>
  </required_header>
  <id_info>
    <org_study_id>115519</org_study_id>
    <nct_id>NCT01439373</nct_id>
  </id_info>
  <brief_title>Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2336805 is a hepatitis C virus (HCV) NS5A inhibitor being developed for the treatment of
      chronic hepatitis C (CHC). This study will assess the safety, antiviral activity, and
      pharmacokinetics of GSK2336805 alone and in combination with peginterferon alfa 2a and
      ribavirin in subjects with chronic hepatitis C (CHC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCV infection is a major public health problem globally and a leading cause of chronic liver
      disease. New medications are needed that are better tolerated and offer a greater chance of
      achieving sustained viral clearance compared to currently available therapy. GSK2336805 is a
      HCV NS5A inhibitor being developed for the treatment of subjects with CHC. This Phase II,
      double blind, randomized, placebo-controlled study will assess the safety, antiviral
      activity, and pharmacokinetics of GSK2336805 alone and in combination with peginterferon
      alfa 2a and ribavirin in subjects with CHC. Subjects will be randomly allocated on a 2:1
      basis to GSK2336805 or matching placebo and will be stratified by IL28B status and HCV viral
      genotype (genotype 1 or 4). The study consists of 2 parts. In Part 1, GSK2336805 or matching
      placebo will be given as single-dose monotherapy (Day 1). In Part 2, GSK2336805 or matching
      placebo will be co-administered with peginterferon alfa-2a and ribavirin through 4 weeks of
      treatment (Days 2 to 28). After completion of Part 2, GSK2336805/matching placebo will be
      discontinued and subjects will be offered continued standard-of-care anti-HCV therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety/tolerability of GSK2336805 in comparison with placebo.</measure>
    <time_frame>28-day treatment period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measured by the nature and frequency of AEs and absolute values and changes over time from predose values for hematology, clinical chemistry, urinalysis, vital signs, and ECG parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV viral load reduction from baseline</measure>
    <time_frame>28-day treatment period</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV viral load reduction from baseline during 24 hours following a single dose of GSK2336805 in comparison with placebo and proportion of subjects achieving rapid virological response, defined as the proportion of subjects below the assay lower limit of detection after 4 weeks of treatment (Day 28) in comparison with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetics, Day 1</measure>
    <time_frame>Pre-dose, 1, 2, 4, 6, 8, 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve (AUC), maximum plasma concentration (Cmax), Time of maximal plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetics, Days 7, 14, 21</measure>
    <time_frame>Post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve (AUC), maximum plasma concentration (Cmax), Time of maximal plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetics, Day 28</measure>
    <time_frame>Pre-dose, 2-4 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve (AUC), maximum plasma concentration (Cmax), Time of maximal plasma concentration (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>GSK2336805</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study Part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2336805 + pegylated interferon alfa-2a + ribavrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + pegylated interferon alfa-2a + ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study Part 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2336805</intervention_name>
    <description>Active Investigational Drug</description>
    <arm_group_label>GSK2336805</arm_group_label>
    <arm_group_label>GSK2336805 + pegylated interferon alfa-2a + ribavrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a</intervention_name>
    <description>Standard of Care drug</description>
    <arm_group_label>Placebo + pegylated interferon alfa-2a + ribavirin</arm_group_label>
    <arm_group_label>GSK2336805 + pegylated interferon alfa-2a + ribavrin</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Standard of Care drug</description>
    <arm_group_label>Placebo + pegylated interferon alfa-2a + ribavirin</arm_group_label>
    <arm_group_label>GSK2336805 + pegylated interferon alfa-2a + ribavrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2336805 Matching Placebo</intervention_name>
    <description>Placebo of Investigational Drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo + pegylated interferon alfa-2a + ribavirin</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documented chronic genotype 1 or genotype 4 HCV infection

          -  Na√Øve to all HCV antiviral treatment(s)

          -  Agree to IL28B genotyping

          -  A body mass index &gt;18 kg/m2 but not exceeding 36 kg/m2

          -  Liver biopsy obtained within 3 years (36 calendar months) prior to the Day 1 visit,
             with a fibrosis classification of non-cirrhotic. If no recent (&lt;36 months) liver
             biopsy is available, a study qualifying biopsy must be performed prior to Baseline
             (Day 1)

          -  All fertile males and females must use two forms of effective contraception between
             them during treatment and during the 24 weeks after treatment ends

          -  Otherwise healthy as determined by the medical history, physical examination, ECG
             findings, and clinical laboratory measurements performed at Screening

        Key Exclusion Criteria:

          -  Positive test at Screening for hepatitis B surface antigen (HBsAg) or anti-human
             immunodeficiency virus antibody

          -  History of any other clinically significant chronic liver disease

          -  History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions
             consistent with decompensated liver disease

          -  Positive results on urine screen for drugs of abuse test at Screening (unless used as
             medical treatment, e.g., with a prescription)

          -  History of alcohol/drug abuse or dependence within 6 months of the study start
             (unless participating in a controlled rehabilitation program)

          -  Screening ECG corrected QT interval value greater than 450 ms and/or clinically
             significant ECG findings

          -  A personal or family history of Torsade de Pointes findings

          -  Pregnant or nursing women

          -  Males with a female partner who is pregnant

          -  Abnormal hematological and biochemical parameters as specified in the protocol

          -  History of major organ transplantation with an existing functional graft

          -  Thyroid dysfunction not adequately controlled

          -  Subjects with a history of suicide attempt or hospitalization for depression in the
             past 5 years and/or any current (within 6 months) severe or poorly controlled
             psychiatric disorder

          -  History or current evidence of immunologic disorder; pulmonary, cardiac, or pulmonary
             disease; seizure disorder; cancer or history of malignancy that in the opinion of the
             investigator makes the subject unsuitable for the study

          -  Participation in a clinical study with an investigational drug, biologic, or device
             within 3 months prior to first dose administration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>November 15, 2012</lastchanged_date>
  <firstreceived_date>July 7, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>NS5A inhibitor</keyword>
  <keyword>ribavirin</keyword>
  <keyword>pegylated interferon</keyword>
  <keyword>GSK2336805</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
